Pyxis Oncology (NASDAQ:PYXS) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock. HC Wainwright also issued estimates for Pyxis Oncology’s Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $0.24 EPS.

Other research analysts have also recently issued reports about the stock. William Blair cut shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price objective (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $9.20.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $1.21 on Wednesday. Pyxis Oncology has a 1 year low of $0.99 and a 1 year high of $6.18. The business’s fifty day moving average is $1.33 and its two-hundred day moving average is $2.36. The stock has a market capitalization of $74.52 million, a P/E ratio of -1.17 and a beta of 1.11.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $16.15 million for the quarter. On average, research analysts forecast that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC purchased a new position in shares of Pyxis Oncology during the 3rd quarter valued at $55,000. ProShare Advisors LLC acquired a new stake in Pyxis Oncology during the fourth quarter valued at $26,000. MetLife Investment Management LLC grew its stake in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after purchasing an additional 5,484 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in Pyxis Oncology in the 4th quarter worth about $35,000. Finally, Caption Management LLC purchased a new stake in shares of Pyxis Oncology during the 4th quarter worth about $35,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.